Cargando…
Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
PURPOSE: Approximately 20% of patients with RAS wild-type metastatic colorectal cancer (mCRC) experience objective responses to the anti-EGFR antibody cetuximab, but disease eradication is seldom achieved. The extent of tumor shrinkage correlates with long-term outcome. We aimed to find rational com...
Autores principales: | Leto, Simonetta M., Ferri, Martina, Sassi, Francesco, Zanella, Eugenia R., Cottino, Francesca, Vurchio, Valentina, Catalano, Irene, Ferrero, Alessandro, Zingaretti, Caterina C., Marchiò, Caterina, Grassi, Elena, Trusolino, Livio, Bertotti, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011886/ https://www.ncbi.nlm.nih.gov/pubmed/36622698 http://dx.doi.org/10.1158/1078-0432.CCR-22-2550 |
Ejemplares similares
-
Discovery of molecular determinants of response to targeted therapies in colorectal cancer using patient-derived xenografts (‘xenopatients’)
por: Sassi, Francesco, et al.
Publicado: (2013) -
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023) -
Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer
por: Cruz-Duarte, Raquel, et al.
Publicado: (2022) -
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
por: Peraldo-Neia, Caterina, et al.
Publicado: (2014) -
Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)